<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52178">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426905</url>
  </required_header>
  <id_info>
    <org_study_id>UNV-TRI-002</org_study_id>
    <nct_id>NCT02426905</nct_id>
  </id_info>
  <brief_title>Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine</brief_title>
  <official_title>Multicentre, Retrospective and Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Univar BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Univar BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to review Wilson disease patients who have previously been prescribed d-
      Penicillamine but were changed to trientine as treatment for their disease, and to follow
      them for a further 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective study to review Wilson disease patients who have previously been prescribed
      d- Penicillamine but were changed to trientine as treatment for their disease, and to follow
      them prospectively for a further 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome specific to the retrospective part of the study</measure>
    <time_frame>48 months</time_frame>
    <description>The clinical course of neurological and hepatic disease for each available time point after initiation of treatment (6, 12, 24, 36, and 48 months, and at the last available time point while taking second line trientine) will be scored (Investigator's score) based on neurological and hepatic status at the time of initiating trientine as: 1 = Unchanged 2 = Improved but not normal 3 = Improved to normal 4 = Asymptomatic over duration of therapy 5 = Worsened.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcome specific to the prospective part of the study</measure>
    <time_frame>12 months</time_frame>
    <description>The clinical course of neurological and hepatic disease will be scored (Investigator's score) based on the status at 6 and 12 months after Baseline as: 1 = Unchanged 2 = Improved but not normal 3 = Improved to normal 4 = Asymptomatic over duration of therapy 5 = Worsened A patient will be counted as a responder if they have a rating of ≤4 at the 12 month visit for both the neurological and hepatic Investigator's score. They will be counted as a non-responder if they have a rating = 5 for one or both scores at the 12 month visit or if they were discontinued from the study for any reason prior to the 12 month visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint Applicable to both the Retrospective and Prospective Parts of the Study</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>All AEs related to trientine treatment, and AEs leading to discontinuation of trientine will be assessed at each available study time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Endpoints for the Prospective Part of the Study</measure>
    <time_frame>12 months</time_frame>
    <description>The QoL questionnaires will be completed for each time point and data will be compared to baseline (prospective part) after 6 and 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Wilson Disease</condition>
  <arm_group>
    <arm_group_label>Retrospective</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trientine dihydrochloride</intervention_name>
    <description>A retrospective review of patients' medical records</description>
    <arm_group_label>Prospective</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 1 year to 90 years of age.

          -  Physician established diagnosis of Wilson disease based on a Ferenci score &gt; 3.

          -  Documented treatment with d-Penicillamine, withdrawal of treatment with d-
             Penicillamine, followed by treatment with trientine for at least 6 months at date of
             informed consent.

          -  Able/willing to provide written informed consent.

          -  For enrolment in the prospective part, enrolment in the retrospective part of the
             study is required.

        Exclusion Criteria:

          -  Incomplete history of medication use for trientine from initial diagnosis to latest
             follow up.

          -  Unavailable outcome data for hepatic and neurological course of disease at assessment
             time points.

          -  Patients with acute liver failure and fulminant hepatic disease with fatal outcome.

          -  Hypersensitivity to trientine and severe anaemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Lawson</last_name>
    <phone>+44 (0) 845 202 6401</phone>
    <email>trientine@univareurope.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kate Simmons</last_name>
    <phone>+44 1780 766824</phone>
    <email>kathryn.simmons@iconplc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Heinz Weiss, Professor</last_name>
      <phone>+49 6221 56 8700</phone>
      <email>Karl-Heinz.Weiss@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Aghia Sophia&quot; Children's Hospital</name>
      <address>
        <city>Goudi</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Paolo Hospital UOC</name>
      <address>
        <city>Milan</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuin, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Dhawan, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>September 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Penicillamine</mesh_term>
    <mesh_term>Trientine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
